Uploaded February 2025 | Updated November 2026, 1 day ago
ATTR-CM is presented here as a rare, progressive heart disease that can be difficult to diagnose. The video explains transthyretin amyloid cardiomyopathy and the burden it can create for patients.
Bayer notes that ATTR-CM affects an estimated 400,000 people globally, while the true prevalence may be higher. The description also points to Bayer’s focus on care and quality of life for people living with the disease.
ATTR-CM is presented here as a rare, progressive heart disease that can be difficult to diagnose. The video explains transthyretin amyloid cardiomyopathy and the burden it can create for patients.
Bayer notes that ATTR-CM affects an estimated 400,000 people globally, while the true prevalence may be higher. The description also points to Bayer’s focus on care and quality of life for people living with the disease.










